Although the trypsin inhibitor is a protein, it avoids being hydrolysed as a substrate by the protease by excluding water from trypsin's active site and destabilising the transition state.
FBXO3
Tocilizumab : Tocilizumab: The first interleukin-6-receptor inhibitor